Hengrui Medicine semi -annual report: net profit decreased by 20.55%year -on -year, and R & D investment created a record high

Author:Red Star News Time:2022.08.19

Red Star Capital August 19 news, Hengrui Pharmaceutical (600276.SH) released the 2022 semi -annual report. According to disclosure, Hengrui Pharmaceutical's revenue in the first half of the year was 10.228 billion yuan, a year -on -year decrease of 23.08%; net profit was 2.119 billion yuan, a year -on -year decrease of decrease 20.55%.

In this regard, Hengrui Pharmaceutical said that the cliff -type decline of the income of generic drugs, the implementation of a new medical insurance negotiation price of multiple innovative drugs, and the domestic epidemic situation caused the company's product sales to be impacted, resulting in a significant decline in the company's income.

Specific to generic drugs, since 2018, Hengrui Pharmaceuticals has a total of 22 varieties in the concentrated volume procurement, with an average of 74.5%of the medium elevation price. According to its disclosure, the company's fifth batch of 8 drugs involved in the fifth batch of pickers in September 2021, in the first half of 2022, sales revenue was 250 million yuan, a decrease of 1.76 billion yuan from the same period last year, a year -on -year decrease of 88%. In addition, after a number of innovative drugs in Hengrui Pharmaceutical implemented a new medical insurance negotiation price, the sales price of medical insurance decreased by 33%.

Hengrui Pharmaceutical said that the impact of profit also includes the continuous rise in major raw and auxiliary materials and energy prices, the continuous rise in logistics costs, and the continued increase in R & D investment.

The Red Star Capital Bureau noticed that in the first half of 2022, Hengrui Pharmaceutical's cumulative R & D investment reached 2.909 billion yuan, an increase of 12.74%year -on -year, and the proportion of R & D investment in sales revenue increased to 28.44%year -on -year, a record high.